Rethink Research Competition Needs Your Vote
The Rethink Research Competition has opened voting for its People’s Choice Award.
The Rethink Research Competition has opened voting for its People’s Choice Award. As industry is aware, recruiting patients for clinical research studies is getting harder and harder every year. The Rethink Research Competition is designed to help industry rebrand itself, similar to what the milk industry did in the 1980’s with its “Got Milk?” campaign.
The four following companies have contributed their ideas for a campaign to help this endeavor: ClinEdge, DAC Patient Recruitment Services, MMG and The Patient Recruiting Agency. To vote for your favorite campaign there is a short version and a long version.
Voting closes on September 30. The winners will be announced at MAGI’s Clinical Research Conference in San Diego, October 11-14, 2015.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
